Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.

Mucosal application of a vaccine can effectively induce both systemic and mucosal immune responses. In general, mucosal applications of antigens result in poor immune responses. Therefore, adjuvant/delivery systems are required to enhance the immune response. Chitosan is a cationic biopolymer which exerts advantages as a vaccine carrier due to its immune stimulating activity and bioadhesive properties that enhance cellular uptake and permeation as well as antigen protection. Similar effects are also shown by chitosan derivatives. In this study, the nanoparticulate systems were prepared by using differently charged chitosan derivatives, N-trimethyl chitosan (TMC, polycationic), and mono-N-carboxymethyl chitosan (MCC, polyampholytic) for mucosal immunisation. The derivatives were synthesised and characterised in-house. The aqueous dispersions of the derivatives were also prepared for comparison. The cytotoxicity studies (MTT assay) on Chinese hamster ovary (CHO-K1) cell lines showed that cell viability was in the order of MCC, chitosan and TMC. Nanoparticles were prepared using ionic gelation method and loaded with tetanus toxoid (TT). Nanoparticles with high loading efficacy (>90% m/m), particle size within the range of 40-400nm, with a negative surface charge for MCC and positive surface charge for TMC and chitosan were obtained. The structural integrity of the TT in the formulations was confirmed by SDS-PAGE electrophoresis analysis. The effective uptake of the FITC-BSA loaded nanoparticles into the cells was demonstrated by cellular uptake studies using J774A.1 cells. Immune responses induced by the formulations loaded with tetanus toxoid were studied in vivo in Balb/c mice. Enhanced immune responses were obtained with intranasal (i.n.) application of nanoparticle formulations. Chitosan and TMC nanoparticles which have positively charged surfaces induced higher serum IgG titres when compared to those prepared with MCC which are negatively charged and smaller in size. Nanoparticle formulations developed in this study can be used as promising adjuvant/delivery systems for mucosal immunisation.

[1]  A. Husband,et al.  Antigen delivery strategies for mucosal vaccines. , 1996, International journal for parasitology.

[2]  Min Huang,et al.  Uptake and Cytotoxicity of Chitosan Molecules and Nanoparticles: Effects of Molecular Weight and Degree of Deacetylation , 2004, Pharmaceutical Research.

[3]  R. Rappuoli,et al.  A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. , 2000, Vaccine.

[4]  A. Vila,et al.  Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  J. Schlom,et al.  Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. , 2007, Vaccine.

[6]  S. Burgalassi,et al.  Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. , 2004, International journal of pharmaceutics.

[7]  D T O'Hagan,et al.  Microparticles for intranasal immunization. , 2001, Advanced drug delivery reviews.

[8]  R. Rappuoli,et al.  The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. , 2003, Vaccine.

[9]  M. Hashida,et al.  In vitro cytotoxicity of macromolecules in different cell culture systems , 1995 .

[10]  A. Panda,et al.  Formulation and Characterization of Immunoreactive Tetanus Toxoid Biodegradable Polymer Particles , 2001, Drug delivery.

[11]  J. Brussee,et al.  Preparation and NMR characterization of highly substitutedN-trimethyl chitosan chloride , 1998 .

[12]  E. Ravichandran,et al.  Trivalent Vaccine against Botulinum Toxin Serotypes A, B, and E That Can Be Administered by the Mucosal Route , 2007, Infection and Immunity.

[13]  Water-based nanoparticulate polymeric system for protein delivery: permeability control and vaccine application. , 2002, Biotechnology and bioengineering.

[14]  Y. S. Rao,et al.  Mucoadhesive microspheres for controlled drug delivery. , 2004, Biological & pharmaceutical bulletin.

[15]  Maria José Alonso,et al.  Comparative Uptake Studies of Bioadhesive and Non-Bioadhesive Nanoparticles in Human Intestinal Cell Lines and Rats: The Effect of Mucus on Particle Adsorption and Transport , 2002, Pharmaceutical Research.

[16]  A. Gebert,et al.  M cells in Peyer's patches of the intestine. , 1996, International review of cytology.

[17]  Gordon L. Amidon,et al.  The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent , 1997, Pharmaceutical Research.

[18]  R. Rappuoli,et al.  Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. , 2004, Vaccine.

[19]  C. Cho,et al.  In vitro study of the immune stimulating activity of an athrophic rhinitis vaccine associated to chitosan microspheres , 2004 .

[20]  S. Şenel,et al.  Potential applications of chitosan in veterinary medicine. , 2004, Advanced drug delivery reviews.

[21]  G. Rosenthal,et al.  ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid. , 2001, Vaccine.

[22]  H. Junginger,et al.  Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[23]  O’Hagan,et al.  Microparticles and polymers for the mucosal delivery of vaccines. , 1998, Advanced drug delivery reviews.

[24]  J. Fell.  Targeting of drugs and delivery systems to specific sites in the gastrointestinal tract. , 1996, Journal of anatomy.

[25]  R. Rappuoli,et al.  Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform , 2005, Journal of drug targeting.

[26]  L. Illum,et al.  Chitosan and its use as a pharmaceutical excipient. , 1998, Pharmaceutical research.

[27]  H. Junginger,et al.  Oral drug absorption enhancement by chitosan and its derivatives. , 2001, Advanced drug delivery reviews.

[28]  G. Russell-Jones,et al.  Lectin-mediated transport of nanoparticles across Caco-2 and OK cells. , 1999, International journal of pharmaceutics.

[29]  H. Junginger,et al.  Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. , 2003, Vaccine.

[30]  Kinam Park,et al.  Immunization of rabbits against a bacterial pathogen with an alginate microparticle vaccine. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[31]  K. Mills,et al.  Immunomodulators and delivery systems for vaccination by mucosal routes. , 2001, Trends in biotechnology.

[32]  M. Neutra,et al.  Targeting of mucosal vaccines to Peyer's patch M cells. , 1997, Behring Institute Mitteilungen.

[33]  H E Junginger,et al.  Chitosan and its derivatives in mucosal drug and vaccine delivery. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[34]  M. Pichichero,et al.  Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine. , 2007, Vaccine.

[35]  Alpar Ho.  Strategies for vaccine delivery. , 2003 .

[36]  R. Read,et al.  Effective nasal influenza vaccine delivery using chitosan. , 2005, Vaccine.

[37]  R. Rappuoli,et al.  Protective Levels of Diphtheria-Neutralizing Antibody Induced in Healthy Volunteers by Unilateral Priming-Boosting Intranasal Immunization Associated with Restricted Ipsilateral Mucosal Secretory Immunoglobulin A , 2003, Infection and Immunity.

[38]  J L Pedraz,et al.  Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. , 2002, Vaccine.

[39]  S. Michalek,et al.  Induction of Protective Immunity againstStreptococcus mutans Colonization after Mucosal Immunization with Attenuated Salmonella enterica Serovar Typhimurium Expressing an S. mutans Adhesin under the Control of In Vivo-Inducible nirB Promoter , 2001, Infection and Immunity.

[40]  Kenneth M. Murphy,et al.  Functional diversity of helper T lymphocytes , 1996, Nature.

[41]  H. Junginger,et al.  N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. , 2007, Vaccine.

[42]  R. Rappuoli,et al.  Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. , 2003, The Journal of infectious diseases.

[43]  C. Jones,et al.  Physicochemical and immunological studies on the stability of free and microsphere-encapsulated tetanus toxoid in vitro. , 1996, Vaccine.

[44]  B. Hirst,et al.  Targeting to intestinal M cells. , 1996, Journal of anatomy.

[45]  L. Babiuk,et al.  Mucosal immune responses following oral immunization with rotavirus antigens encapsulated in alginate microspheres. , 2002, Journal of controlled release : official journal of the Controlled Release Society.